Retraining and Control Therapy (ReACT) R33 Phase

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age11-18
SponsorUniversity of Alabama at Birmingham

About this trial

The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of pediatric psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 11-18-year-olds diagnosed with PNES will engage in twelve sessions of either ReACT or supportive therapy. Sense of control over actions will be measured by the magic and turbulence task, a well-validated measure of sense of control. Participants will complete the cold pressor test (CPT) in which participants hold their hand in cool water for as long as possible up to 3 minutes. Catastrophic symptom expectations in response to the CPT will be measured by Pain Catastrophizing Scale for Children (PCS-C), pain tolerance (time with hand in water) and cortisol response. Target assessments occur 7 days before treatment, 7 days after 12th treatment session, and 2 months after the 12th treatment session. Long term follow-up assessments will occur 6 months and 12 months after the 12th treatment session. PNES frequency will be measured from 30 days before to 12 months after treatment.

Eligibility criteria

Qualifiers

11-18 years old.

Diagnosis of psychogenic non-epileptic seizures by a medical doctor using video-EEG.

Family member (parent/guardian if a minor) willing to participate and that the subject with PNES chooses.

Disqualifiers

Comorbid Epilepsy

Less than 4 PNES per month

Other paroxysmal nonepileptic events (e.g. episodes related to hypoxic-ischemic phenomena, sleep disorders or migraine-associated disorders)

Participation in other therapy during the study

Trial design

Treatments tested in this trial

  • ReACT
  • Supportive Therapy

Treatment groups

160 Participants
are divided into 3 treatment groups

Sponsors and collaborators

University of Alabama at Birmingham

Lead sponsor

National Institute of Mental Health (NIMH)

Collaborator